Shots:
- GlycoNex has dosed the last patient with SPD8, a biosimilar version of Prolia/Xgeva (denosumab), in its P-III trial for the treatment of primary osteoporosis from solid tumors
- Trial will assess the PK, efficacy, & safety of SPD8 vs reference denosumab in postmenopausal women with osteoporosis; top-line results are expected in Q2’26 & data will support global registration
- Additionally, SPD8 has been out-licensed in select regions, with discussions ongoing with several companies for additional territory-specific development & commercialization partnerships
Ref: PRNewsWire| Image: GlycoNex | Press Release
Related News:- GlycoNex Reports Licensing Agreement to Develop SPD8 (Biosimilar, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
